Metabolic regulation by signal transduction and post-translational modification
Post-translational modification (PTM) is a hallmark of metabolic regulation. Protein structure and function can be rapidly and reversibly modulated by the addition or removal of small chemical groups, such as phosphate in the case of protein phosphorylation. Typically, these PTMs are part of a cascade, linking target proteins (e.g. glycolytic enzymes, gluconeogenic enzymes, etc.) to a receptor (e.g. the insulin receptor) via multiple relay enzymes — a process known as signal transduction. We are especially interested in how signal transduction can go awry in human diseases and how proper function can be restored — particularly as it pertains to insulin resistance leading to type 2 diabetes mellitus, and reversal of that resistance by novel bioactive agents (both naturally-occurring and synthetic).
Medical devices and other biotechnologies
In addition to fundamental or basic research, our expertise also includes or applied research — this stems from Chris’ time at Micropharma Ltd, a biotech startup that was acquired by UAS Labs in December 2014. Past and current projects have involved the development of gut-friendly probiotics targeted against specific diseases — including diabetes, high cholesterol, hypertension, and liver disease. Chris also worked on the development of a gaseous nitric oxide-generating medical dressing with wound-healing and antimicrobial/anti-biofilm activity. Thus, amidst our fundamental research work, we always have translational goals in mind.
Nanotoxicology and nanopharmacology
Engineered nanomaterials (ENMs) are the core component of most modern-day nanotechnologies. With increasing use, there is elevated risk that ENMs are improperly disposed of and accidentally released into the environment. At the nanoscale, ENMs are at a comparable biological scale to subcellular biomolecules such as large proteins; they therefore have the ability to penetrate living cells and influence their physiology — potentially in a deleterious manner. We therefore study the mechanisms by which ENMs are nanotoxic — but by the same token, we also investigate how ENMs can be safely exploited as delivery vehicles to different biological compartments (i.e. cell-specific drug-targeting).